• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Genetic Analysis AS: Genetic Analysis to attend DDW congress in Chicago

Genetic Analysis

OSLO, NORWAY, April 30, 2026: Microbiome DX company Genetic Analysis AS ("GA") announces its attendance at Digestive Disease Week (DDW) congress in Chicago, May 3 - May 5 2026. The company will use the meeting to highlight its upcoming product, GA-map® IBD Precision Dx, a next-generation diagnostic solution for personalized management in inflammatory bowel disease (IBD).

DDW offers an opportunity to gain the latest insights in the Gastrointestinal field, while providing valuable networking and partnering opportunities. Genetic Analysis' Head of Commercial, Kari Furu, Christina Casén, SVP Clinical, and Medical and Zuzanna Gulczynska, Product & Marketing Manager, will attend the congress.

GA will use the event to highlight how GA's microbiome testing platform, GA-map®, can be used for the discovery of novel microbiome-based biomarkers and development of new precision medicine strategies. Specifically, GA will showcase its pipeline product, the GA-map® IBD Precision Dx, the first microbiome-based biomarker for early Ulcerative Colitis (UC) patient stratification. The test enables identification of a microbiome profile associated with aggressive disease, thereby providing prognostic guidance and aid in treatment planning.

Genetic Analysis will also contribute to the scientific program during the meeting:

Sunday, May 3 - 8:00 AM

Kari Furu will give a short presentation introducing Genetic Analysis and our work in gut microbiome innovation during a session hosted by the American Gastroenterological Association (AGA) Gut Microbiome Center and Committee for GI Innovation and Technology.

Monday, May 4 - Poster Session (12:30 - 1:30 PM) | Poster Mo1428

Ken Blount (Ferring Pharmaceuticals), together with Christina Casén, will present our collaborative work with Ferring Pharmaceuticals on: "Monitoring Gut Microbiome Restoration in Patients With Antibiotic-Associated C. difficile Infection".

Attendance at DDW provides an important platform to engage with key stakeholders and supports the company's ongoing efforts to advance its microbiome-based diagnostics pipeline.

Visit this link to read more about the DDW congress: https://ddw.org/